DZ Bank Reiterates “Buy” Rating for Qiagen (NYSE:QGEN)

DZ Bank restated their buy rating on shares of Qiagen (NYSE:QGEN) in a report released on Thursday morning, Borsen Zeitung reports.

QGEN has been the subject of several other reports. Zacks Investment Research upgraded Qiagen from a sell rating to a hold rating and set a $32.00 price objective for the company in a research report on Monday, November 4th. Barclays cut Qiagen from an overweight rating to an equal weight rating and set a $32.00 target price on the stock. in a report on Tuesday, October 8th. Deutsche Bank cut Qiagen from a buy rating to a hold rating in a report on Tuesday, October 8th. Bank of America dropped their target price on Qiagen from $40.00 to $33.00 and set a neutral rating on the stock in a report on Tuesday, October 8th. Finally, Kepler Capital Markets raised Qiagen from a reduce rating to a hold rating in a report on Thursday. Ten analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of $35.38.

Shares of NYSE QGEN traded up $3.28 during midday trading on Thursday, hitting $40.56. 8,251,151 shares of the company’s stock were exchanged, compared to its average volume of 2,209,234. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.45 and a quick ratio of 2.18. The stock’s 50 day moving average price is $30.26 and its 200-day moving average price is $35.64. The firm has a market cap of $7.99 billion, a P/E ratio of 30.27, a PEG ratio of 2.64 and a beta of 0.83. Qiagen has a twelve month low of $25.04 and a twelve month high of $41.55.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $0.36 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.35 by $0.01. The business had revenue of $382.70 million during the quarter, compared to the consensus estimate of $382.98 million. Qiagen had a positive return on equity of 12.24% and a negative net margin of 1.68%. The business’s revenue was up 1.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.35 earnings per share. On average, analysts expect that Qiagen will post 1.4 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Massachusetts Financial Services Co. MA increased its holdings in shares of Qiagen by 3.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 12,525,258 shares of the company’s stock valued at $412,957,000 after buying an additional 471,654 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Qiagen by 3.0% in the second quarter. Vanguard Group Inc. now owns 7,070,710 shares of the company’s stock valued at $286,718,000 after buying an additional 206,294 shares in the last quarter. D. E. Shaw & Co. Inc. increased its holdings in shares of Qiagen by 28.6% in the second quarter. D. E. Shaw & Co. Inc. now owns 2,195,033 shares of the company’s stock valued at $89,011,000 after buying an additional 487,844 shares in the last quarter. Waddell & Reed Financial Inc. increased its holdings in shares of Qiagen by 134.5% in the second quarter. Waddell & Reed Financial Inc. now owns 1,913,610 shares of the company’s stock valued at $77,597,000 after buying an additional 1,097,432 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in shares of Qiagen by 199.7% in the second quarter. Invesco Ltd. now owns 1,821,967 shares of the company’s stock valued at $73,880,000 after buying an additional 1,213,968 shares in the last quarter. 61.95% of the stock is currently owned by institutional investors.

About Qiagen

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Further Reading: Convertible Shares

Analyst Recommendations for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.